subjects will be treated with HBM4003 in combination with Toripalimab for up to 2 years or until confirmed disease progression, unacceptable tolerability or treatment discontinuation through withdrawal of consent occurs, whichever happens first.~This trial consists of :~A screening period: 28 days~A treatment period:~Part 1 dose confirmation study~Part 2 dose expansion study~A post-treatment follow-up period, including~A safety follow-up period: 28 days after the last dose of study drug;~Post-treatment follow-up visit: day 84 after the last dose of study drug;~Survival follow-up.
This is an open-label, multi-center phase 1 study. The trial, consisting of Part~1 dose confirmation and Part 2 dose expansion, is designed to evaluate the safety, tolerability, PK/PD and preliminary efficacy of HBM4003 in combination with Toripalimab in patients with advanced HCC and other solid tumors.